Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of NPC-15 for Sleep Initiation Difficulty in Mild Cognitive Impairment
jRCT2071230029Phase 2Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of melatonin in Mild Cognitive Impairment (MCI) and Insomnia (4 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Sleep onset latency based on actigraphy. Started Jul 2023; status: completed.
02
Drugs
melatonin
03
Conditions
Mild Cognitive Impairment (MCI)Insomnia
Beyond the preview
Go deeper on jRCT2071230029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230029.